Acquired RD3 loss regulates immune surveillance in high-risk and therapy defying progressive neuroblastoma  

作　　者：Poorvi Subramanian Sreenidhi Mohanvelu Dinesh Babu Somasundaram Sheeja Aravindan Natarajan Aravindan 

机构地区：[1]Department of Physiological Sciences,Oklahoma State University,Stillwater,Oklahoma,USA [2]Stephenson Cancer Center,Oklahoma City,Oklahoma,USA

出　　处：《Cancer Communications》2024年第12期1427-1430,共4页癌症通讯(英文)

基　　金：funded by Department of Defense(DoD CA-210339);Oklahoma Center for the Advancement of Science and Technology(OCAST-HR19-045);the National Institutes of Health(P20GM103639);supported by the National Cancer Institute Cancer Center Support Grant(P30CA225520);a grant from the Oklahoma Tobacco Settlement Endowment Trust(R23-03)both awarded to the OU Health Stephenson Cancer Center.

摘　　要：Neuroblastoma(NB)is the most common extra cranial solid tumor in children and comprises one tenth of all childhood cancer deaths.More than half of infants presented with NB,a designated“cold tumor”with low immune cell repertoire in the tumor microenvironment(TME)[1],develop progressive disease(PD).

关 键 词：NEUROBLASTOMA IMMUNE tumor 

分 类 号：R73[医药卫生—肿瘤]